APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pharmaceutical API and Intermediates

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pharmaceutical API and Intermediates Market Outlook and Growth Opportunities 2026

Report ID 173327790422 December 2025218 pages

Choose your research edition.

Industry ResearchPharmaceutical API and Intermediates Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharmaceutical API and Intermediates Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Pharmaceutical API and Intermediates Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharmaceutical API and Intermediates Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharmaceutical API and Intermediates Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Pharmaceutical API and Intermediates market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pharmaceutical API and Intermediates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pharmaceutical API and Intermediates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pharmaceutical API and Intermediates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pharmaceutical API and Intermediates market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pharmaceutical API and Intermediates market include Lonza, BASF, Patheon, Lianhetech, Jubilant, Catalent, ABA Chem, Actylis and Chiracon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pharmaceutical API and Intermediates market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pharmaceutical API and Intermediates and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pharmaceutical API and Intermediates sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pharmaceutical API and Intermediates market size, projected growth trends, production technologies, key applications, and end-use industries.

Pharmaceutical API and Intermediates Segment by Company

Lonza

BASF

Patheon

Lianhetech

Jubilant

Catalent

ABA Chem

Actylis

Chiracon

Codexis

CordenPharma

Granules India

Pfizer

Porton

Sanofi

Jiuzhou Pharmaceutical

Menohua

Puluo Pharmaceutical

Stanley

Tianyu shares

Huahai Pharmaceutical

Pharmaceutical API and Intermediates Segment by Type

API

Pharmaceutical Intermediates

Pharmaceutical API and Intermediates Segment by Application

Pharmaceutical

Feed

Food

Cosmetics

Health Products

Pharmaceutical API and Intermediates Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pharmaceutical API and Intermediates status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pharmaceutical API and Intermediates market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pharmaceutical API and Intermediates significant trends, drivers, influence factors in global and regions.

6. To analyze Pharmaceutical API and Intermediates competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmaceutical API and Intermediates market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharmaceutical API and Intermediates and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmaceutical API and Intermediates.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pharmaceutical API and Intermediates market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pharmaceutical API and Intermediates industry.

Chapter 3: Detailed analysis of Pharmaceutical API and Intermediates manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pharmaceutical API and Intermediates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pharmaceutical API and Intermediates in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pharmaceutical API and Intermediates Industry Trends Table 2. Pharmaceutical API and Intermediates Industry Drivers Table 3. Pharmaceutical API and Intermediates Industry Opportunities and Challenges Table 4. Pharmaceutical API and Intermediates Industry Restraints Table 5. Global Pharmaceutical API and Intermediates Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pharmaceutical API and Intermediates Revenue Share by Company (2021-2026) Table 7. Global Pharmaceutical API and Intermediates Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Pharmaceutical API and Intermediates Sales Volume Share by Company (2021-2026) Table 9. Global Pharmaceutical API and Intermediates Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Pharmaceutical API and Intermediates Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pharmaceutical API and Intermediates Key Company Manufacturing Base & Headquarters Table 12. Global Pharmaceutical API and Intermediates Company, Product Type & Application Table 13. Global Pharmaceutical API and Intermediates Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pharmaceutical API and Intermediates by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of API Table 18. Significant Companies of Pharmaceutical Intermediates Table 19. Global Pharmaceutical API and Intermediates Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 20. Global Pharmaceutical API and Intermediates Sales Volume by Type (2021-2026) & (Tons) Table 21. Global Pharmaceutical API and Intermediates Sales Volume by Type (2027-2032) & (Tons) Table 22. Global Pharmaceutical API and Intermediates Sales Volume Share by Type (2021-2026) Table 23. Global Pharmaceutical API and Intermediates Sales Volume Share by Type (2027-2032) Table 24. Global Pharmaceutical API and Intermediates Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Pharmaceutical API and Intermediates Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Pharmaceutical API and Intermediates Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Pharmaceutical API and Intermediates Sales Value Share by Type (2021-2026) Table 28. Global Pharmaceutical API and Intermediates Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Pharmaceutical Table 30. Significant Companies of Feed Table 31. Significant Companies of Food Table 32. Significant Companies of Cosmetics Table 33. Significant Companies of Health Products Table 34. Global Pharmaceutical API and Intermediates Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 35. Global Pharmaceutical API and Intermediates Sales Volume by Application (2021-2026) & (Tons) Table 36. Global Pharmaceutical API and Intermediates Sales Volume by Application (2027-2032) & (Tons) Table 37. Global Pharmaceutical API and Intermediates Sales Volume Share by Application (2021-2026) Table 38. Global Pharmaceutical API and Intermediates Sales Volume Share by Application (2027-2032) Table 39. Global Pharmaceutical API and Intermediates Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Pharmaceutical API and Intermediates Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Pharmaceutical API and Intermediates Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Pharmaceutical API and Intermediates Sales Value Share by Application (2021-2026) Table 43. Global Pharmaceutical API and Intermediates Sales Value Share by Application (2027-2032) Table 44. Global Pharmaceutical API and Intermediates Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 45. Global Pharmaceutical API and Intermediates Sales by Region (2021-2026) & (Tons) Table 46. Global Pharmaceutical API and Intermediates Sales Market Share by Region (2021-2026) Table 47. Global Pharmaceutical API and Intermediates Sales by Region (2027-2032) & (Tons) Table 48. Global Pharmaceutical API and Intermediates Sales Market Share by Region (2027-2032) Table 49. Global Pharmaceutical API and Intermediates Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Pharmaceutical API and Intermediates Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Pharmaceutical API and Intermediates Sales Value Share by Region (2021-2026) Table 52. Global Pharmaceutical API and Intermediates Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Pharmaceutical API and Intermediates Sales Value Share by Region (2027-2032) Table 54. Global Pharmaceutical API and Intermediates Market Average Price (US$/Ton) by Region (2021-2026) Table 55. Global Pharmaceutical API and Intermediates Market Average Price (US$/Ton) by Region (2027-2032) Table 56. Global Pharmaceutical API and Intermediates Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 57. Global Pharmaceutical API and Intermediates Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Pharmaceutical API and Intermediates Sales by Country (2021-2026) & (Tons) Table 59. Global Pharmaceutical API and Intermediates Sales Market Share by Country (2021-2026) Table 60. Global Pharmaceutical API and Intermediates Sales by Country (2027-2032) & (Tons) Table 61. Global Pharmaceutical API and Intermediates Sales Market Share by Country (2027-2032) Table 62. Global Pharmaceutical API and Intermediates Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Pharmaceutical API and Intermediates Sales Value Market Share by Country (2021-2026) Table 64. Global Pharmaceutical API and Intermediates Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Pharmaceutical API and Intermediates Sales Value Market Share by Country (2027-2032) Table 66. Lonza Company Information Table 67. Lonza Business Overview Table 68. Lonza Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 69. Lonza Pharmaceutical API and Intermediates Product Portfolio Table 70. Lonza Recent Development Table 71. BASF Company Information Table 72. BASF Business Overview Table 73. BASF Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 74. BASF Pharmaceutical API and Intermediates Product Portfolio Table 75. BASF Recent Development Table 76. Patheon Company Information Table 77. Patheon Business Overview Table 78. Patheon Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 79. Patheon Pharmaceutical API and Intermediates Product Portfolio Table 80. Patheon Recent Development Table 81. Lianhetech Company Information Table 82. Lianhetech Business Overview Table 83. Lianhetech Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 84. Lianhetech Pharmaceutical API and Intermediates Product Portfolio Table 85. Lianhetech Recent Development Table 86. Jubilant Company Information Table 87. Jubilant Business Overview Table 88. Jubilant Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 89. Jubilant Pharmaceutical API and Intermediates Product Portfolio Table 90. Jubilant Recent Development Table 91. Catalent Company Information Table 92. Catalent Business Overview Table 93. Catalent Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 94. Catalent Pharmaceutical API and Intermediates Product Portfolio Table 95. Catalent Recent Development Table 96. ABA Chem Company Information Table 97. ABA Chem Business Overview Table 98. ABA Chem Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 99. ABA Chem Pharmaceutical API and Intermediates Product Portfolio Table 100. ABA Chem Recent Development Table 101. Actylis Company Information Table 102. Actylis Business Overview Table 103. Actylis Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 104. Actylis Pharmaceutical API and Intermediates Product Portfolio Table 105. Actylis Recent Development Table 106. Chiracon Company Information Table 107. Chiracon Business Overview Table 108. Chiracon Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 109. Chiracon Pharmaceutical API and Intermediates Product Portfolio Table 110. Chiracon Recent Development Table 111. Codexis Company Information Table 112. Codexis Business Overview Table 113. Codexis Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 114. Codexis Pharmaceutical API and Intermediates Product Portfolio Table 115. Codexis Recent Development Table 116. CordenPharma Company Information Table 117. CordenPharma Business Overview Table 118. CordenPharma Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 119. CordenPharma Pharmaceutical API and Intermediates Product Portfolio Table 120. CordenPharma Recent Development Table 121. Granules India Company Information Table 122. Granules India Business Overview Table 123. Granules India Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 124. Granules India Pharmaceutical API and Intermediates Product Portfolio Table 125. Granules India Recent Development Table 126. Pfizer Company Information Table 127. Pfizer Business Overview Table 128. Pfizer Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 129. Pfizer Pharmaceutical API and Intermediates Product Portfolio Table 130. Pfizer Recent Development Table 131. Porton Company Information Table 132. Porton Business Overview Table 133. Porton Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 134. Porton Pharmaceutical API and Intermediates Product Portfolio Table 135. Porton Recent Development Table 136. Sanofi Company Information Table 137. Sanofi Business Overview Table 138. Sanofi Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 139. Sanofi Pharmaceutical API and Intermediates Product Portfolio Table 140. Sanofi Recent Development Table 141. Jiuzhou Pharmaceutical Company Information Table 142. Jiuzhou Pharmaceutical Business Overview Table 143. Jiuzhou Pharmaceutical Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 144. Jiuzhou Pharmaceutical Pharmaceutical API and Intermediates Product Portfolio Table 145. Jiuzhou Pharmaceutical Recent Development Table 146. Menohua Company Information Table 147. Menohua Business Overview Table 148. Menohua Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 149. Menohua Pharmaceutical API and Intermediates Product Portfolio Table 150. Menohua Recent Development Table 151. Puluo Pharmaceutical Company Information Table 152. Puluo Pharmaceutical Business Overview Table 153. Puluo Pharmaceutical Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 154. Puluo Pharmaceutical Pharmaceutical API and Intermediates Product Portfolio Table 155. Puluo Pharmaceutical Recent Development Table 156. Stanley Company Information Table 157. Stanley Business Overview Table 158. Stanley Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 159. Stanley Pharmaceutical API and Intermediates Product Portfolio Table 160. Stanley Recent Development Table 161. Tianyu shares Company Information Table 162. Tianyu shares Business Overview Table 163. Tianyu shares Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 164. Tianyu shares Pharmaceutical API and Intermediates Product Portfolio Table 165. Tianyu shares Recent Development Table 166. Huahai Pharmaceutical Company Information Table 167. Huahai Pharmaceutical Business Overview Table 168. Huahai Pharmaceutical Pharmaceutical API and Intermediates Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 169. Huahai Pharmaceutical Pharmaceutical API and Intermediates Product Portfolio Table 170. Huahai Pharmaceutical Recent Development Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. Pharmaceutical API and Intermediates Distributors List Table 174. Pharmaceutical API and Intermediates Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Pharmaceutical API and Intermediates Product Image Figure 2. Global Pharmaceutical API and Intermediates Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pharmaceutical API and Intermediates Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pharmaceutical API and Intermediates Sales (2021-2032) & (Tons) Figure 5. Global Pharmaceutical API and Intermediates Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Pharmaceutical API and Intermediates Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. API Image Figure 10. Pharmaceutical Intermediates Image Figure 11. Global Pharmaceutical API and Intermediates Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 12. Global Pharmaceutical API and Intermediates Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Pharmaceutical API and Intermediates Sales Volume Share by Type (2021-2032) Figure 14. Global Pharmaceutical API and Intermediates Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Pharmaceutical API and Intermediates Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Pharmaceutical API and Intermediates Sales Value Share by Type (2021-2032) Figure 17. Pharmaceutical Image Figure 18. Feed Image Figure 19. Food Image Figure 20. Cosmetics Image Figure 21. Health Products Image Figure 22. Global Pharmaceutical API and Intermediates Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 23. Global Pharmaceutical API and Intermediates Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Pharmaceutical API and Intermediates Sales Volume Share by Application (2021-2032) Figure 25. Global Pharmaceutical API and Intermediates Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Pharmaceutical API and Intermediates Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Pharmaceutical API and Intermediates Sales Value Share by Application (2021-2032) Figure 28. Global Pharmaceutical API and Intermediates Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 29. Global Pharmaceutical API and Intermediates Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Pharmaceutical API and Intermediates Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Pharmaceutical API and Intermediates Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Pharmaceutical API and Intermediates Sales Value (2021-2032) & (US$ Million) Figure 33. North America Pharmaceutical API and Intermediates Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Pharmaceutical API and Intermediates Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Pharmaceutical API and Intermediates Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Pharmaceutical API and Intermediates Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Pharmaceutical API and Intermediates Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Pharmaceutical API and Intermediates Sales Value (2021-2032) & (US$ Million) Figure 39. South America Pharmaceutical API and Intermediates Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Pharmaceutical API and Intermediates Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Pharmaceutical API and Intermediates Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Pharmaceutical API and Intermediates Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Pharmaceutical API and Intermediates Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • API
  • Pharmaceutical Intermediates
Applications
  • Pharmaceutical
  • Feed
  • Food
  • Cosmetics
  • Health Products
Companies covered
  • Lonza
  • BASF
  • Patheon
  • Lianhetech
  • Jubilant
  • Catalent
  • ABA Chem
  • Actylis
  • Chiracon
  • Codexis
  • CordenPharma
  • Granules India
  • Pfizer
  • Porton
  • Sanofi
  • Jiuzhou Pharmaceutical
  • Menohua
  • Puluo Pharmaceutical
  • Stanley
  • Tianyu shares
  • Huahai Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pharmaceutical API and Intermediates Sales Value (2021-2032)
  4. 1.2.2 Global Pharmaceutical API and Intermediates Sales Volume (2021-2032)
  5. 1.2.3 Global Pharmaceutical API and Intermediates Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pharmaceutical API and Intermediates Market Dynamics
  1. 2.1 Pharmaceutical API and Intermediates Industry Trends
  2. 2.2 Pharmaceutical API and Intermediates Industry Drivers
  3. 2.3 Pharmaceutical API and Intermediates Industry Opportunities and Challenges
  4. 2.4 Pharmaceutical API and Intermediates Industry Restraints
3 Pharmaceutical API and Intermediates Market by Company
  1. 3.1 Global Pharmaceutical API and Intermediates Company Revenue Ranking in 2025
  2. 3.2 Global Pharmaceutical API and Intermediates Revenue by Company (2021-2026)
  3. 3.3 Global Pharmaceutical API and Intermediates Sales Volume by Company (2021-2026)
  4. 3.4 Global Pharmaceutical API and Intermediates Average Price by Company (2021-2026)
  5. 3.5 Global Pharmaceutical API and Intermediates Company Ranking (2024-2026)
  6. 3.6 Global Pharmaceutical API and Intermediates Company Manufacturing Base and Headquarters
  7. 3.7 Global Pharmaceutical API and Intermediates Company Product Type and Application
  8. 3.8 Global Pharmaceutical API and Intermediates Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pharmaceutical API and Intermediates Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pharmaceutical API and Intermediates Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pharmaceutical API and Intermediates Market by Type
  1. 4.1 Pharmaceutical API and Intermediates Type Introduction
  2. 4.1.1 API
  3. 4.1.2 Pharmaceutical Intermediates
  4. 4.2 Global Pharmaceutical API and Intermediates Sales Volume by Type
  5. 4.2.1 Global Pharmaceutical API and Intermediates Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pharmaceutical API and Intermediates Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Pharmaceutical API and Intermediates Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Pharmaceutical API and Intermediates Sales Value by Type
  9. 4.3.1 Global Pharmaceutical API and Intermediates Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Pharmaceutical API and Intermediates Sales Value by Type (2021-2032)
  11. 4.3.3 Global Pharmaceutical API and Intermediates Sales Value Share by Type (2021-2032)
5 Pharmaceutical API and Intermediates Market by Application
  1. 5.1 Pharmaceutical API and Intermediates Application Introduction
  2. 5.1.1 Pharmaceutical
  3. 5.1.2 Feed
  4. 5.1.3 Food
  5. 5.1.4 Cosmetics
  6. 5.1.5 Health Products
  7. 5.2 Global Pharmaceutical API and Intermediates Sales Volume by Application
  8. 5.2.1 Global Pharmaceutical API and Intermediates Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Pharmaceutical API and Intermediates Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Pharmaceutical API and Intermediates Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Pharmaceutical API and Intermediates Sales Value by Application
  12. 5.3.1 Global Pharmaceutical API and Intermediates Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Pharmaceutical API and Intermediates Sales Value by Application (2021-2032)
  14. 5.3.3 Global Pharmaceutical API and Intermediates Sales Value Share by Application (2021-2032)
6 Pharmaceutical API and Intermediates Regional Sales and Value Analysis
  1. 6.1 Global Pharmaceutical API and Intermediates Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pharmaceutical API and Intermediates Sales by Region (2021-2032)
  3. 6.2.1 Global Pharmaceutical API and Intermediates Sales by Region: 2021-2026
  4. 6.2.2 Global Pharmaceutical API and Intermediates Sales by Region (2027-2032)
  5. 6.3 Global Pharmaceutical API and Intermediates Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pharmaceutical API and Intermediates Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pharmaceutical API and Intermediates Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pharmaceutical API and Intermediates Sales Value by Region (2027-2032)
  9. 6.5 Global Pharmaceutical API and Intermediates Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pharmaceutical API and Intermediates Sales Value (2021-2032)
  12. 6.6.2 North America Pharmaceutical API and Intermediates Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pharmaceutical API and Intermediates Sales Value (2021-2032)
  15. 6.7.2 Europe Pharmaceutical API and Intermediates Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pharmaceutical API and Intermediates Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pharmaceutical API and Intermediates Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pharmaceutical API and Intermediates Sales Value (2021-2032)
  21. 6.9.2 South America Pharmaceutical API and Intermediates Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pharmaceutical API and Intermediates Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pharmaceutical API and Intermediates Sales Value Share by Country, 2025 VS 2032
7 Pharmaceutical API and Intermediates Country-level Sales and Value Analysis
  1. 7.1 Global Pharmaceutical API and Intermediates Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pharmaceutical API and Intermediates Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pharmaceutical API and Intermediates Sales by Country (2021-2032)
  4. 7.3.1 Global Pharmaceutical API and Intermediates Sales by Country (2021-2026)
  5. 7.3.2 Global Pharmaceutical API and Intermediates Sales by Country (2027-2032)
  6. 7.4 Global Pharmaceutical API and Intermediates Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pharmaceutical API and Intermediates Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pharmaceutical API and Intermediates Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pharmaceutical API and Intermediates Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pharmaceutical API and Intermediates Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pharmaceutical API and Intermediates Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Lonza
  2. 8.1.1 Lonza Company Information
  3. 8.1.2 Lonza Business Overview
  4. 8.1.3 Lonza Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Lonza Pharmaceutical API and Intermediates Product Portfolio
  6. 8.1.5 Lonza Recent Developments
  7. 8.2 BASF
  8. 8.2.1 BASF Company Information
  9. 8.2.2 BASF Business Overview
  10. 8.2.3 BASF Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 BASF Pharmaceutical API and Intermediates Product Portfolio
  12. 8.2.5 BASF Recent Developments
  13. 8.3 Patheon
  14. 8.3.1 Patheon Company Information
  15. 8.3.2 Patheon Business Overview
  16. 8.3.3 Patheon Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Patheon Pharmaceutical API and Intermediates Product Portfolio
  18. 8.3.5 Patheon Recent Developments
  19. 8.4 Lianhetech
  20. 8.4.1 Lianhetech Company Information
  21. 8.4.2 Lianhetech Business Overview
  22. 8.4.3 Lianhetech Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Lianhetech Pharmaceutical API and Intermediates Product Portfolio
  24. 8.4.5 Lianhetech Recent Developments
  25. 8.5 Jubilant
  26. 8.5.1 Jubilant Company Information
  27. 8.5.2 Jubilant Business Overview
  28. 8.5.3 Jubilant Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Jubilant Pharmaceutical API and Intermediates Product Portfolio
  30. 8.5.5 Jubilant Recent Developments
  31. 8.6 Catalent
  32. 8.6.1 Catalent Company Information
  33. 8.6.2 Catalent Business Overview
  34. 8.6.3 Catalent Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Catalent Pharmaceutical API and Intermediates Product Portfolio
  36. 8.6.5 Catalent Recent Developments
  37. 8.7 ABA Chem
  38. 8.7.1 ABA Chem Company Information
  39. 8.7.2 ABA Chem Business Overview
  40. 8.7.3 ABA Chem Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 ABA Chem Pharmaceutical API and Intermediates Product Portfolio
  42. 8.7.5 ABA Chem Recent Developments
  43. 8.8 Actylis
  44. 8.8.1 Actylis Company Information
  45. 8.8.2 Actylis Business Overview
  46. 8.8.3 Actylis Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Actylis Pharmaceutical API and Intermediates Product Portfolio
  48. 8.8.5 Actylis Recent Developments
  49. 8.9 Chiracon
  50. 8.9.1 Chiracon Company Information
  51. 8.9.2 Chiracon Business Overview
  52. 8.9.3 Chiracon Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Chiracon Pharmaceutical API and Intermediates Product Portfolio
  54. 8.9.5 Chiracon Recent Developments
  55. 8.10 Codexis
  56. 8.10.1 Codexis Company Information
  57. 8.10.2 Codexis Business Overview
  58. 8.10.3 Codexis Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Codexis Pharmaceutical API and Intermediates Product Portfolio
  60. 8.10.5 Codexis Recent Developments
  61. 8.11 CordenPharma
  62. 8.11.1 CordenPharma Company Information
  63. 8.11.2 CordenPharma Business Overview
  64. 8.11.3 CordenPharma Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 CordenPharma Pharmaceutical API and Intermediates Product Portfolio
  66. 8.11.5 CordenPharma Recent Developments
  67. 8.12 Granules India
  68. 8.12.1 Granules India Company Information
  69. 8.12.2 Granules India Business Overview
  70. 8.12.3 Granules India Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Granules India Pharmaceutical API and Intermediates Product Portfolio
  72. 8.12.5 Granules India Recent Developments
  73. 8.13 Pfizer
  74. 8.13.1 Pfizer Company Information
  75. 8.13.2 Pfizer Business Overview
  76. 8.13.3 Pfizer Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer Pharmaceutical API and Intermediates Product Portfolio
  78. 8.13.5 Pfizer Recent Developments
  79. 8.14 Porton
  80. 8.14.1 Porton Company Information
  81. 8.14.2 Porton Business Overview
  82. 8.14.3 Porton Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Porton Pharmaceutical API and Intermediates Product Portfolio
  84. 8.14.5 Porton Recent Developments
  85. 8.15 Sanofi
  86. 8.15.1 Sanofi Company Information
  87. 8.15.2 Sanofi Business Overview
  88. 8.15.3 Sanofi Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Sanofi Pharmaceutical API and Intermediates Product Portfolio
  90. 8.15.5 Sanofi Recent Developments
  91. 8.16 Jiuzhou Pharmaceutical
  92. 8.16.1 Jiuzhou Pharmaceutical Company Information
  93. 8.16.2 Jiuzhou Pharmaceutical Business Overview
  94. 8.16.3 Jiuzhou Pharmaceutical Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Jiuzhou Pharmaceutical Pharmaceutical API and Intermediates Product Portfolio
  96. 8.16.5 Jiuzhou Pharmaceutical Recent Developments
  97. 8.17 Menohua
  98. 8.17.1 Menohua Company Information
  99. 8.17.2 Menohua Business Overview
  100. 8.17.3 Menohua Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Menohua Pharmaceutical API and Intermediates Product Portfolio
  102. 8.17.5 Menohua Recent Developments
  103. 8.18 Puluo Pharmaceutical
  104. 8.18.1 Puluo Pharmaceutical Company Information
  105. 8.18.2 Puluo Pharmaceutical Business Overview
  106. 8.18.3 Puluo Pharmaceutical Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Puluo Pharmaceutical Pharmaceutical API and Intermediates Product Portfolio
  108. 8.18.5 Puluo Pharmaceutical Recent Developments
  109. 8.19 Stanley
  110. 8.19.1 Stanley Company Information
  111. 8.19.2 Stanley Business Overview
  112. 8.19.3 Stanley Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Stanley Pharmaceutical API and Intermediates Product Portfolio
  114. 8.19.5 Stanley Recent Developments
  115. 8.20 Tianyu shares
  116. 8.20.1 Tianyu shares Company Information
  117. 8.20.2 Tianyu shares Business Overview
  118. 8.20.3 Tianyu shares Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Tianyu shares Pharmaceutical API and Intermediates Product Portfolio
  120. 8.20.5 Tianyu shares Recent Developments
  121. 8.21 Huahai Pharmaceutical
  122. 8.21.1 Huahai Pharmaceutical Company Information
  123. 8.21.2 Huahai Pharmaceutical Business Overview
  124. 8.21.3 Huahai Pharmaceutical Pharmaceutical API and Intermediates Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Huahai Pharmaceutical Pharmaceutical API and Intermediates Product Portfolio
  126. 8.21.5 Huahai Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pharmaceutical API and Intermediates Value Chain Analysis
  2. 9.1.1 Pharmaceutical API and Intermediates Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pharmaceutical API and Intermediates Sales Mode & Process
  6. 9.2 Pharmaceutical API and Intermediates Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pharmaceutical API and Intermediates Distributors
  9. 9.2.3 Pharmaceutical API and Intermediates Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst